MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.

**Synonyms:** - MVA-209-FSP - Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP - Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP